Abstract
Programmed cell death, commonly associated with the term apoptosis, is an integrated intracellular program that plays a critical role in lymphoid tissue homeostasis. Alterations in this highly regulated process is a common feature of most lymphoid malignancies, thus facilitating tumor escape from traditional chemotherapeutic agents whose main endpoint is the induction of tumor cell death. In the last years, enormous progress has been made in understanding the deregulated signals that could lead to ineffective apoptosis in B lymphoid tumors. Consequently, several new strategies have been designed to modulate the key molecules of life-and-death decisions. Numerous novel approaches are being validated and some of them have progressed to clinical testing or have even been approved in a record time. In this review we will focus on current therapies that have demonstrated to trigger efficiently cell death in B lymphoid neoplasms, either by directly targeting the intracellular apoptotic machinery or by modulating different factors involved in its regulation.
Keywords: Apoptosis, B lymphoid malignancies, targeted therapies
Current Drug Targets
Title: Cell Death Targeting Therapies in B Lymphoid Malignancies
Volume: 11 Issue: 7
Author(s): I. Saborit-Villarroya, G. Roue, M. Lopez-Guerra, R. Alonso, S. Xargay-Torrent, L. Rosich and D. Colomer
Affiliation:
Keywords: Apoptosis, B lymphoid malignancies, targeted therapies
Abstract: Programmed cell death, commonly associated with the term apoptosis, is an integrated intracellular program that plays a critical role in lymphoid tissue homeostasis. Alterations in this highly regulated process is a common feature of most lymphoid malignancies, thus facilitating tumor escape from traditional chemotherapeutic agents whose main endpoint is the induction of tumor cell death. In the last years, enormous progress has been made in understanding the deregulated signals that could lead to ineffective apoptosis in B lymphoid tumors. Consequently, several new strategies have been designed to modulate the key molecules of life-and-death decisions. Numerous novel approaches are being validated and some of them have progressed to clinical testing or have even been approved in a record time. In this review we will focus on current therapies that have demonstrated to trigger efficiently cell death in B lymphoid neoplasms, either by directly targeting the intracellular apoptotic machinery or by modulating different factors involved in its regulation.
Export Options
About this article
Cite this article as:
Saborit-Villarroya I., Roue G., Lopez-Guerra M., Alonso R., Xargay-Torrent S., Rosich L. and Colomer D., Cell Death Targeting Therapies in B Lymphoid Malignancies, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320863
DOI https://dx.doi.org/10.2174/138945010791320863 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Current Radiopharmaceuticals An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity
Current Medicinal Chemistry Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Molecular Phenotyping of Mouse Mutant Resources by RNA Expression Profiling
Current Genomics Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy NK Cell Function in HIV-1 Infection
Current HIV Research Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics